[News Article]PharmAbcine, a clinical stage immuno-oncology company announced that PharmAbcine is so proud to be a sponsor of the 11th COGNO Annual Scientific Meeting,

14 Jan 2019
Title
PharmAbcine, a clinical stage immuno-oncology company announced that PharmAbcine is so proud to be a sponsor of the 11th COGNO Annual Scientific Meeting,
Category
News Article


Dr. Jin-San Yoo, chairman and chief Executive Officer of PharmAbcine will attend the conference to meet Dr. Anna Nowak (New President of COGNO) and Dr. Lawrence Cher (Previous President of COGNO) who were PI of Tanibirumab (TTAC-0001) phase IIa recurrent GBM clinical trials and active PIs for Avastin refractory recurrent GBM phase II Tanibirumab clinical trials, recurrent GBM phase IB/II Tanibirumab + Keytruda combination clinical trials,  recurrent GBM phase IIB Tanibirumab clinical trials.


PharmAbcine also sponsored for COGNO-ASM2017.





For investors attending the COGNO-ASM2018, please contact PharmAbcine Investor Relations and business development to schedule a meeting with management at sungwoo.kim@pharmabcine.com.  





     2F, Research Building 2, 70,

     Yuseong-daero 1689 beon-gil,
     Yuseong-gu, Daejeon, 34047, Republic of Korea


     HQ +82-42-863-2017 

     R&D Center +82-42-861-2017

     Investor Relations +70-4294-6097 

     FAX +82-42-863-2080 


     COPYRIGHT BY PharmAbcine Inc.

     ALL RIGHTS RESERVE